Ketamine is a promising therapeutic option in treatment-resistant depression (TRD). The
acute efficacy of ketamine in TRD has been demonstrated in replicated randomised …

The off-label use of racemic ketamine and the FDA approval of (S)-ketamine are promising
developments for the treatment of depression. Nevertheless, racemic ketamine and (S) …

Abstract Major Depressive Disorder (MDD) is a serious neuropsychiatric disorder afflicting
around 16–17% of the global population and is accompanied by recurrent episodes of low …

Despite the thousands of lives lost during the ongoing opioid crisis, a scarcity of new and
effective clinical treatments for opioid use disorder (OUD) remains. To address this unmet …

Abstract (2R, 6R)-Hydroxynorketamine (HNK), a ketamine metabolite, has been proposed
as an ideal next-generation antidepressant due to its rapid-acting and long-lasting …

Abstract (2R, 6R)-hydroxynorketamine (HNK) is a metabolite of ketamine that exerts rapid
and sustained antidepressant-like effects in preclinical studies. We hypothesize that the …

Ketamine is clinically used fast-acting antidepressant. Its metabolite hydroxynorketamine
(HNK) shows a robust antidepressant effect in animal studies. It is unclear, how these …

Economic development and increased stress have considerably increased the prevalence
of psychiatric disorders in recent years, which rank as some of the most prevalent diseases …

Rationale Fear memory, a fundamental symptom of post-traumatic stress disorder (PTSD), is
improved by (2R, 6R)-hydroxynorketamine ((2R, 6R)-HNK) administration. However, the …

Mice are the most commonly used preclinical animal model, but protein analytics of murine
cerebrospinal fluid (CSF) remains challenging because of low CSF volume (often< 10 …